Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients

Chemotherapy

Volumn 54, Issue 6, 2008, Pages 421-424

  Brandi, G ^a,b   Nannini, M ^a   Pantaleo, M A ^a   Fanello, S ^a   Farsad, M ^b   Fanti, S ^b   Ercolani, G ^b   Maleddu, A ^a   Di Battista, M ^a   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Advanced colorectal cancer; Bevacizumab; PET

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; CANCER GROWTH; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; PERITONITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 52549092180     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158540     Document Type: Article

References (11)

1. Kabbinavar FF, Hambleton J, Mass RDM, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
2. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Cancer 2004;350:2335-2342.
4. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W: Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004;8:S50-S52.
5. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
6. Airley RE, Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-256.
7. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C: We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
8. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E: Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006;17:117-122.
9. Goshen E, Davidson T, Zwas ST, et al: PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006;5:37-43.
10. Bird NC, Mangnall D, Majeed AW: Biology of colorectal liver metastases: a review. J Surg Oncol 2006;94:68-80.
11. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, Boschi S, Biasco G: Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 2008;34:103-121.